We understand the complexities of mass tort claims and are committed to securing justice for those harmed by negligent drug manufacturers
Johnson & Johnson Johnson & Johnson leverages its extensive healthcare ecosystem to develop and distribute GLP-1 targeted therapies while focusing on patient education and support programs
If the application is accepted and approved, the medication could become available as early as late 2027, although the timeline will ultimately depend on the FDA review process
bmj.com/content/392/bm NEW: In a study of 600,000 people published today in @bmj_latest, we found GLP-1 drugs (Ozempic, Wegovy, Mounjaro) associated with reduced risk of addiction across alcohol, opioids, cocaine, cannabis, nicotineand 50% fewer substance-related deaths
Before choosing, it is helpful to ask your provider and pharmacy about coverage, expected monthly cost, and whether your plan requires documentation of BMI, weight-related conditions, or previous treatment attempts